Skip to main content

Table 2 Patient Characteristics 2

From: Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis

Case Age (y) Gender Smoking Histology EGFR mutation PFS to 1st TKI TKI sequence Interval from 1st and 2nd Chemo. after 1st PS Response PFS to 2nd TKI OS from 2nd TKI
1 50 F Current Ad NA 9.8 G→E 7.9 CBDCA+GEM 1 PD 0.9 13.1
2 46 F Never Ad NA 11.8 G→G 4.5 DOC 1 PR 6.4 24.6
3 58 F Ex Ad 19 deletion 38.4 G→G 2.8 DOC 1 SD 7.3 24.1
4 70 F Never Sq NA 10.2 G→E 12.8 GEM 1 SD 1.7 4.3
5 60 F Never Ad NA 13 G→G 5.4 GEM 1 PD 1.6 2.1
6 63 F Never Ad NA 7.4 G→E 2.6 - 3 SD 3.6 7.8
7 52 M Never Ad L858R 5.8 G→E 1 - 4 SD 6.4 6.4
8 51 M Current Ad NA 4.3 G→E 1.6 AMR 3 PD 0.6 0.9
9 61 F Never Ad NA 8.5 G→E 2.3 VNR 3 SD 2.9 4
10 53 F Never Ad NA 12.9 G→E 0 - 4 SD 6.2 7.3
11 54 M Current Ad 19 deletion 3.8 G→E 7.3 VNR 1 SD 3.2 5
  1. PFS, progression-free survival; TKI, tyrosine kinase inhibitor; PS, performance status; OS, overall survival; F, female; M, male; Ex, ex-smoker; Ad, adenocarcinoma; Sq, squamous cell carcinoma; G, gefitinib; E, erlotinib; CBDCA, carboplatin; GEM, gemcitabine; DOC, docetaxel; AMR, amrubicin; VNR, vinorelbine; PR, partial response; SD, stable disease; PD, progressive disease.
\